At the news
? BEARISHIMPACT 6/10 8-K filed May 6, 2026 at 16:50 ET
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.
- Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
- Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
- SG&A expense $171M, up 36% from $126M YoY, driving operating loss
- DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access